QRG Capital Management Inc. Sells 37,675 Shares of Smith & Nephew SNATS, Inc. $SNN

QRG Capital Management Inc. decreased its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 42.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,462 shares of the medical equipment provider’s stock after selling 37,675 shares during the quarter. QRG Capital Management Inc.’s holdings in Smith & Nephew SNATS were worth $1,831,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of SNN. Bank of Montreal Can grew its holdings in shares of Smith & Nephew SNATS by 321.6% in the second quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock valued at $105,056,000 after purchasing an additional 2,616,301 shares in the last quarter. River Road Asset Management LLC raised its stake in Smith & Nephew SNATS by 9.3% during the second quarter. River Road Asset Management LLC now owns 3,179,814 shares of the medical equipment provider’s stock valued at $97,175,000 after purchasing an additional 270,480 shares in the last quarter. Scharf Investments LLC lifted its position in Smith & Nephew SNATS by 0.3% during the second quarter. Scharf Investments LLC now owns 2,083,513 shares of the medical equipment provider’s stock valued at $63,818,000 after purchasing an additional 6,993 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after buying an additional 583,809 shares in the last quarter. Finally, Brandes Investment Partners LP increased its holdings in shares of Smith & Nephew SNATS by 4.1% in the 2nd quarter. Brandes Investment Partners LP now owns 1,604,400 shares of the medical equipment provider’s stock worth $49,143,000 after buying an additional 63,778 shares during the last quarter. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Stock Down 0.5%

NYSE:SNN opened at $32.71 on Tuesday. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a twelve month low of $23.91 and a twelve month high of $38.79. The stock has a fifty day simple moving average of $32.96 and a 200-day simple moving average of $34.32.

Analyst Upgrades and Downgrades

SNN has been the subject of a number of analyst reports. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Sanford C. Bernstein set a $37.50 price objective on Smith & Nephew SNATS and gave the company a “market perform” rating in a research report on Tuesday, October 14th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, October 8th. Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 10th. Finally, Canaccord Genuity Group lowered their price target on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $35.75.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.